DK1677833T3 - Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom - Google Patents
Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdomInfo
- Publication number
- DK1677833T3 DK1677833T3 DK04791259.7T DK04791259T DK1677833T3 DK 1677833 T3 DK1677833 T3 DK 1677833T3 DK 04791259 T DK04791259 T DK 04791259T DK 1677833 T3 DK1677833 T3 DK 1677833T3
- Authority
- DK
- Denmark
- Prior art keywords
- neurturin
- gene therapy
- vivo gene
- parkinson
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301543 | 2003-10-20 | ||
US51291803P | 2003-10-22 | 2003-10-22 | |
PCT/EP2004/052586 WO2005039643A2 (en) | 2003-10-20 | 2004-10-20 | In vivo gene therapy of parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1677833T3 true DK1677833T3 (da) | 2010-05-17 |
Family
ID=34524307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04791259.7T DK1677833T3 (da) | 2003-10-20 | 2004-10-20 | Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP2210617A1 (da) |
JP (1) | JP2007509109A (da) |
KR (1) | KR20060095568A (da) |
AT (1) | ATE460183T1 (da) |
AU (1) | AU2004283053A1 (da) |
BR (1) | BRPI0415563A (da) |
CA (1) | CA2543189A1 (da) |
DE (1) | DE602004025959D1 (da) |
DK (1) | DK1677833T3 (da) |
ES (1) | ES2342397T3 (da) |
MX (1) | MXPA06004329A (da) |
NZ (1) | NZ547185A (da) |
RU (1) | RU2006117304A (da) |
WO (1) | WO2005039643A2 (da) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
ES2323066T3 (es) | 2003-06-10 | 2009-07-06 | Nsgene A/S | Secrecion mejorada de neublastina. |
US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
BRPI0514409A (pt) | 2004-08-19 | 2008-06-10 | Biogen Idec Inc | redobra de proteìnas da famìlia de fator de crescimento transformante beta |
WO2007048413A1 (en) * | 2005-10-28 | 2007-05-03 | Nsgene A/S | IMPLANTABLE BIOCOMPATIBLE IMMtTNOISOLATORY VEHICLE FOR DELIVERY OF GDNF |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
EP2142205B1 (en) | 2007-05-01 | 2014-04-02 | Biogen Idec MA Inc. | Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow |
MX2010004899A (es) * | 2007-11-05 | 2010-09-07 | Develogen Ag | Conjugados de neurturina novedosos para uso farmaceutico. |
DK3192874T3 (da) * | 2008-06-18 | 2019-12-16 | Oxford Biomedica Ltd | Virusoprensning |
WO2011053675A2 (en) * | 2009-10-30 | 2011-05-05 | Cns Therapeutics, Inc. | Improved neurturin molecules |
US9149427B2 (en) * | 2010-12-02 | 2015-10-06 | Neurotech Usa, Inc. | Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof |
EP2661494B1 (en) | 2011-01-07 | 2019-06-12 | Applied Genetic Technologies Corporation | Promoters, expression cassettes and vectors for use treating achromatopsia and other diseases |
EP2870237B1 (en) * | 2012-07-06 | 2018-09-26 | University of Iowa Research Foundation | Modified adeno-associated virus vector compositions |
WO2014028461A2 (en) | 2012-08-13 | 2014-02-20 | The Rockefeller University | Treatment and diagnosis of melanoma |
AU2013337768B2 (en) | 2012-10-31 | 2015-07-02 | The Rockefeller University | Treatment and diagnosis of colon cancer |
CN103981147B (zh) | 2013-02-08 | 2017-11-10 | 中国科学院上海生命科学研究院 | 一种新的制备肝实质细胞的方法 |
WO2016179497A1 (en) | 2015-05-07 | 2016-11-10 | Shire Human Genetic Therapies, Inc. | Glucocerebrosidase gene therapy for parkinson's disease |
US10016514B2 (en) * | 2015-05-15 | 2018-07-10 | New Hope Research Foundation | Polynucleotides, vectors and methods for insertion and expression of transgenes |
WO2017081082A2 (en) * | 2015-11-09 | 2017-05-18 | Curevac Ag | Optimized nucleic acid molecules |
EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
US11174220B2 (en) | 2019-12-13 | 2021-11-16 | Inspirna, Inc. | Metal salts and uses thereof |
WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2703893B2 (ja) | 1985-07-05 | 1998-01-26 | ホワイトヘッド・インスティテュ−ト・フォ−・バイオメディカル・リサ−チ | 外来遺伝子物質を発現する上皮細胞 |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
EP0378576B1 (en) | 1987-09-11 | 1995-01-18 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5156844A (en) | 1987-11-17 | 1992-10-20 | Brown University Research Foundation | Neurological therapy system |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5487739A (en) | 1987-11-17 | 1996-01-30 | Brown University Research Foundation | Implantable therapy systems and methods |
DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
DK0585368T3 (da) | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
EP0708670A4 (en) | 1993-06-23 | 1998-07-01 | Cytotherapeutics Inc | METHOD AND APPARATUS FOR HERMETICALLY CLOSING IMPLANTABLE MEMBRANE ENCAPSULATING DEVICES |
EP1179350A3 (en) | 1993-08-12 | 2003-01-02 | Cytotherapeutics, Inc. | Encapsulated cell system for implantation into the human CNS |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
US20020031493A1 (en) | 1994-03-25 | 2002-03-14 | Rhone-Poulenc Rorer S.A. | Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf) |
EP0755454B1 (en) | 1994-04-13 | 2008-02-13 | The Rockefeller University | Aav-mediated delivery of dna to cells of the nervous system |
US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
US5677158A (en) | 1995-06-07 | 1997-10-14 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
US6184200B1 (en) | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US5904144A (en) | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
US6027721A (en) | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
EP1304119A3 (en) * | 1997-07-30 | 2004-01-21 | Amgen Inc. | Method for preventing and treating hearing loss using a neurturin protein product |
US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
US6303136B1 (en) | 1998-04-13 | 2001-10-16 | Neurotech S.A. | Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane |
US6451306B1 (en) | 1998-04-15 | 2002-09-17 | The Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
ATE435917T1 (de) | 1998-05-27 | 2009-07-15 | Genzyme Corp | Aav vektoren zur herstellung der medikamente zur konvektion-erhöhten verabreichung |
US20020055467A1 (en) | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
US6361741B1 (en) | 1999-02-01 | 2002-03-26 | Alcoa Inc. | Brazeable 6XXX alloy with B-rated or better machinability |
US6361771B1 (en) | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
JP2003534787A (ja) | 2000-05-26 | 2003-11-25 | カイロン コーポレイション | レンチウイルスベクターを使用する神経細胞の形質導入の方法 |
US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
US6800281B2 (en) | 2000-11-09 | 2004-10-05 | Oxford Biomedica (Uk) Limited | Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases |
US20030050273A1 (en) | 2001-08-29 | 2003-03-13 | Keiya Ozawa | Compositions and methods for treating neurodegenerative diseases |
-
2004
- 2004-10-20 AU AU2004283053A patent/AU2004283053A1/en not_active Abandoned
- 2004-10-20 CA CA002543189A patent/CA2543189A1/en not_active Abandoned
- 2004-10-20 NZ NZ547185A patent/NZ547185A/en not_active IP Right Cessation
- 2004-10-20 EP EP10155955A patent/EP2210617A1/en not_active Withdrawn
- 2004-10-20 DK DK04791259.7T patent/DK1677833T3/da active
- 2004-10-20 RU RU2006117304/15A patent/RU2006117304A/ru unknown
- 2004-10-20 AT AT04791259T patent/ATE460183T1/de not_active IP Right Cessation
- 2004-10-20 WO PCT/EP2004/052586 patent/WO2005039643A2/en active Application Filing
- 2004-10-20 EP EP04791259A patent/EP1677833B1/en not_active Not-in-force
- 2004-10-20 DE DE602004025959T patent/DE602004025959D1/de active Active
- 2004-10-20 MX MXPA06004329A patent/MXPA06004329A/es not_active Application Discontinuation
- 2004-10-20 ES ES04791259T patent/ES2342397T3/es active Active
- 2004-10-20 KR KR1020067007666A patent/KR20060095568A/ko not_active Application Discontinuation
- 2004-10-20 BR BRPI0415563-7A patent/BRPI0415563A/pt not_active Application Discontinuation
- 2004-10-20 JP JP2006536086A patent/JP2007509109A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2005039643A3 (en) | 2005-11-17 |
BRPI0415563A (pt) | 2007-01-02 |
AU2004283053A1 (en) | 2005-05-06 |
ES2342397T3 (es) | 2010-07-06 |
CA2543189A1 (en) | 2005-05-06 |
JP2007509109A (ja) | 2007-04-12 |
ATE460183T1 (de) | 2010-03-15 |
DE602004025959D1 (de) | 2010-04-22 |
KR20060095568A (ko) | 2006-08-31 |
WO2005039643A2 (en) | 2005-05-06 |
MXPA06004329A (es) | 2006-06-05 |
NZ547185A (en) | 2009-03-31 |
EP1677833A2 (en) | 2006-07-12 |
EP1677833B1 (en) | 2010-03-10 |
RU2006117304A (ru) | 2007-12-10 |
EP2210617A1 (en) | 2010-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1677833T3 (da) | Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom | |
EA200800368A1 (ru) | Гликозилированный il-7, получение и применение | |
WO2005077333A3 (en) | Gel-based delivery of recombinant adeno-associated virus vectors | |
WO2003104270A3 (en) | GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES | |
WO2004022716A3 (en) | Recombinatant mutants of rhabdovirus and methods of use thereof | |
BE2014C077I2 (da) | ||
EP1315965A4 (en) | METHODS AND COMPOSITIONS FOR IN VITRO TARGETING | |
EP1140971A4 (en) | ANTISENS MODULATION OF NEW ANTI-APOPTOTIC BCL-2-LIKE PROTEINS | |
BR0207110A (pt) | Pró-peptìdeos de gdf modificados e estabilizados e usos dos mesmos | |
HK1111674A1 (en) | Multivalent vla-4 antagonists comprising polyethylene glycol moieties | |
AU9063801A (en) | Methods and compositions for diseases associated with amyloidosis | |
WO1998049300A3 (en) | Truncated vegf-related proteins | |
CY1107351T1 (el) | Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης | |
IL142989A0 (en) | Nucleotide and protein sequences of nogo genes and methods based thereon | |
DK1745069T3 (da) | Terapeutisk anvendelse af vækstfaktoren NSG33 | |
ATE457359T1 (de) | Auf lps-reagierendes chs1/beige-ähnliches anker- gen und therapeutische anwendungen davon | |
DE60328673D1 (de) | Optimierung von transgenexpression in säugetierzellen | |
EP1209226A3 (en) | Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70) | |
HUP0500637A2 (hu) | Neublasztin polimer konjugátumai és alkalmazási eljárásai | |
DE60129069D1 (de) | Hepatitis B Virus Vektoren für Gentherapie | |
ATE529438T1 (de) | Dna-sequenz und rekombinante herstellung des graspollen-allergens lol p 4 | |
ATE371737T1 (de) | Proteaseresistente flint-analoge | |
EP1090995A3 (en) | Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof | |
WO2004074312A3 (en) | Tryptophyllin peptides and uses thereof | |
WO2006072601A3 (en) | THERAPEUTIC USE OF GROWTH FACTORS, NsG29 AND NsG31 |